Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Journal of the National Cancer Institute|November 9, 2015
Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain MicroenvironmentVasileios Askoxylakis, Gino B Ferraro, David P Kodack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2018
Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic CancerAdam J Camblin, Emily A Pace, Sharlene Adams, et al.
Journal for Immunotherapy of Cancer|March 13, 2026
Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancerFrancois Ghiringhelli, Richard Kim, Teresa Macarulla, et al.
Nature Biomedical Engineering|April 6, 2019
Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithiumGiorgio Seano, Hadi T Nia, Kyrre E Emblem, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 5, 2016
Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survivalJonas Kloepper, Lars Riedemann, Zohreh Amoozgar, et al.
Nature Biomedical Engineering|April 7, 2019
Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse modelsWalid S Kamoun, Dmitri B Kirpotin, Zhaohua Richard Huang, et al.
Oncoimmunology|January 3, 2024
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignanciesChia-Chi Lin, Elena Garralda, Patrick Schöffski, et al.
Journal for Immunotherapy of Cancer|February 26, 2022
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignanciesPatrick Schöffski, Daniel S W Tan, Miguel Martín, et al.
Science Translational Medicine|May 26, 2017
The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activationDavid P Kodack, Vasileios Askoxylakis, Gino B Ferraro, et al.
Pageof 5